ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Takeda bets on Japan R&D hub for next blockbuster drug

Success of homegrown medicine key to Japanese company's global ambitions

Takeda President Christophe Weber announced an increase in R&D spending for the fiscal year ending March 2022. (Photo by Taro Yokosawa)

TOKYO -- Takeda Pharmaceutical's state-of-the-art research and development center in the waterfront city of Shonan has yet to yield a blockbuster treatment since its founding a decade ago -- a weak track record the Japanese drugmaker is determined to improve.

"The Shonan base has made a significant contribution to neuroscience," said Takashi Ichikawa, who heads the company's neuroscience research unit, on a conference call explaining Takeda's R&D efforts. "Shonan's pharmaceutical science level is recognized globally," he said.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more